Insera Therapeutics has announced that it has received CE mark approval for its flagship product, the CLEAR Aspiration System, for the aspiration of blood clots, and is indicated for use in patients with acute ischaemic stroke secondary to intracranial large vessel occlusive disease, secondary to cerebral venous sinus thrombosis, and optionally for staged aspiration through a balloon guide or guide catheter within the neck arteries.
This unique aspiration technology offers the ability to vary the vacuum suction pressures and intervals within the safe vacuum suction range up to -98.2 kPa (-29 inHg). A recent study using the CLEAR aspiration system showed that complete clot ingestion with cyclical aspiration (namely varying the suction pressures) increases first-pass recanalisation (namely ability to achieve full vessel re-opening using a single retrieval attempt) and reduces clot fragmentation compared to static aspiration (namely uniform suction pressure).
Approval was based on mechanical bench tests, safety and efficacy tests conducted in premier stroke device testing centres including: Intertek Electrical (Menlo Park, USA), Mayo Clinic (Rochester, USA) New England Center for Stroke Research (NECStR; Worcester, USA) and The Jacobs Institute in Buffalo (USA).
The catheterisations in Buffalo were performed by the Jacobs Institute’s chief medical officer and SUNY at Buffalo Professor of Neurosurgery, Adnan Siddiqui, who noted: “The CLEAR Aspiration System includes a best-in-class, next-generation vacuum aspiration system that allows operators to employ uniform suction or cyclical suction patterns. The digital pump is powerful, easy-to-use, and can be operated remotely from an iPad, giving it an advantage over its competitors.”
The CLEAR Aspiration System has CE mark approval for the aspiration of tissue and fluids in addition to blood clots, and is indicated for use in patients with haemorrhagic stroke or brain bleeds, for the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum, during neurosurgical, neuro-endoscopic, and other surgical procedures, including aspiration of tissue, fluids, tumour, and abscess.
The CLEAR aspiration system also has European regulatory approval for the aspiration of foreign bodies in addition to blood clots, and is indicated for use for foreign body retrieval in the peripheral, neuro, and cardiovasculature, for the aspiration of blood clots from arteries (e.g. in patients with peripheral artery disease, pulmonary embolism, and coronary artery disease), and for the aspiration of blood clots from veins (e.g. in patients with deep venous thrombosis, or patients with renal failure who have clotted haemodialysis grafts).
“CLEAR’s proprietary power electronics technology for vacuum aspiration allows for the customisation of both uniform and variable suction pressures within the safe vacuum suction range, all with an eye towards improving complete clot ingestion and a higher first-pass effect,” explained Vikram Janardhan, CEO of Insera Therapeutics.
